Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
The internationally recognized Comprehensive Hemophilia Treatment Center at New York Presbyterian and Weill Cornell Medicine was founded more than 50 years ago by Dr. Margaret Hilgartner. In 1960, Dr. Carl Smith, then Chief of Pediatrics at Cornell University, introduced Margaret to coagulation and by 1966, she headed Cornell's hemophilia program developing the first classification of hemophilic arthropathy, which became the gold standard for assessing orthopedic outcomes and concept of self-infusion and comprehensive care to patients of all ages in New York City. Her contributions to the field included transfusion treatments, autoimmune responses, inhibitors, and the infectious complications of hepatitis and HIV. Margaret’s legacy as a pioneer in hemophilia care has been carried on at the Center through leadership by Dr. Donna DiMichele’s innovative work in immune tolerance clinical trials and current exciting research collaborations focused on gene transfer therapy at the Comprehensive Hemophilia Treatment Center.
The Center now comprises a team of multisciplinary professionals dedicated to clinical care and research in the field of hemophilia and other bleeding disorders.
We invite you to explore our web site to learn about our Center and the services we have to offer.
